微創醫療(00853.HK)年度淨利潤預增超88%
格隆匯1月21日丨微創醫療(00853.HK)發佈公告,截至2019年12月31日止12個月,集團成功錄得不低於4500萬美元的歸屬於公司權益股東的年內利潤,相比於去年同期的2390萬美元增長不低於88%。
公告表示,期內歸屬於公司權益股東的年內利潤增加主要由於(i)心血管介入產品分部業務的藥物支架產品收入顯著增長,同比增長率超過30%(剔除匯率影響);(ii)大動脈與外周血管產品分部業務及神經介入產品分部業務由於新產品迅速推廣而帶動收入強勁增長;(iii)心臟瓣膜產品分部業務的第一代產品VitaFlow順利上市並獲得積極的市場認可;(iv)骨科醫療器械分部中國市場收入增長迅猛,同比增長率超過45%(剔除匯率影響),部分彌補了國際骨科業務失去北美主要代理商的短期影響;(v)處置上海微創電生理醫療科技股份有限公司部分股權獲取的投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.